HoldsUp

Tony Robbins

Tony Robbins is an entrepreneur, author, philanthropist, and business strategist. He works in business and life coaching, delivering content through audio programs, educational videos, and live seminars. The provided material does not list any academic research publications.

18 claims checked on air: 3 context 2 contradicted 5 overstated 3 supported 5 unverified

What they said on air

0:01:24unverifiedvery lowPeter Diamandis and Tony Robbins on strategies that promote

Cristiano Ronaldo returned to play in two and a half weeks instead of being out for three months due to stem cell treatment.

"You know, someone like Cristiano Ronaldo was supposed to be out for three months, it was two and a half weeks and he's back on because of stem cells." (said at 0:01:24)

No published record matching the claim that Cristiano Ronaldo received stem cell treatment allowing him to return to play in two and a half weeks instead of three months was located; this does not prove the claim false.

0:04:04overstatedmoderatePeter Diamandis and Tony Robbins on strategies that promote

Autologous stem cell levels drop dramatically after age 40, making them ineffective for extensive tissue repair.

"Bob said, "Listen, using your own stem cells is a waste of time. After 40, they drop through the floor." He said, "If you're doing an elbow or an ankle or something, maybe." But he said, "This is really extensive. You need four-day-old stem cells."" (said at 0:04:04)

While scientific literature confirms that donor aging correlates with a gradual decline in the clonogenic and proliferative potential of bone marrow-derived mesenchymal stem cells (MSCs), claiming that autologous stem cells 'drop through the floor' after age 40 or are a 'waste of time' for tissue repair is an overstatement. Systematic reviews evaluating chronological age and stem cell potency show that age-related functional changes occur gradually across decades rather than dropping precipitously at age 40, and outcomes regarding differentiation and regenerative potential remain heterogeneous across tissue sources (such as adipose-derived vs. bone marrow-derived stem cells).

0:05:28unverifiedvery lowPeter Diamandis and Tony Robbins on strategies that promote

Jack Nicklaus underwent stem cell treatment for severe back pain instead of spinal fusion and was able to return to playing golf and tennis at age 82.

"I met, you know, Jack Nicklaus, one of the greatest golfers of all time. He couldn't stand for more than 10 minutes, his pain was so severe. They were going to, you know, lock up, you know, give him a spinal fusion, which as I'm sure you know doesn't usually work, at least half the time, and if it does, gives you limited mobility. He did stem cells instead, and here he was, 82 years old, now playing golf and tennis." (said at 0:05:28)

No published record matching the claim that Jack Nicklaus underwent stem cell treatment for severe back pain in place of spinal fusion and returned to golf and tennis at age 82 was located; this does not prove the claim false. While Nicklaus has spoken publicly in media interviews about receiving experimental adipose-derived stem cell therapy in Germany for chronic back pain, this anecdotal clinical account has not been published as a peer-reviewed case report or formal clinical study.

0:05:34needs contextmoderatePeter Diamandis and Tony Robbins on strategies that promote

Spinal fusion surgery for chronic back pain does not work at least half of the time.

"They were going to, you know, lock up, you know, give him a spinal fusion, which as I'm sure you know doesn't usually work, at least half the time, and if it does, gives you limited mobility." (said at 0:05:34)

Spinal fusion for chronic low back pain associated with degenerative disc disease has substantial evidence demonstrating limited clinical superiority over intensive non-operative rehabilitation, along with significant complication rates and frequent persistent pain (often termed failed back surgery syndrome). Systematic reviews and meta-analyses of randomized trials indicate that lumbar fusion yields little to no clinically meaningful difference in pain or disability scores compared to non-operative multidisciplinary care, although quantifying this strictly as 'failing at least half the time' requires qualification based on how success (e.g., pain reduction thresholds versus return-to-work or complication rates) is measured.

0:10:17contradictedhighPeter Diamandis and Tony Robbins on strategies that promote

Biosplice's osteoarthritis treatment is a single injection that regrows all tendons in 11 months to the state of 16-year-old tendons.

"And so the one they're getting approval for first is for osteoarthritis. It's a single injection, and in 11 months you regrow all your tendons, but based on the boot disk as what's just described, they're like 16-year-old tendons, even if you're 40, 50, 60, or 70 years old." (said at 0:10:17)

Biosplice Therapeutics developed lorecivivint (SM04690), an intra-articular CLK/DYRK and Wnt pathway inhibitor, as an investigational disease-modifying drug targeting cartilage and inflammation in knee osteoarthritis—not tendon regeneration. In Phase 3 randomized controlled trials (such as OA-10 and OA-11) and systematic meta-analyses, a single injection of lorecivivint failed to meet primary endpoints for pain reduction and did not demonstrate significant structural regeneration or joint space improvement compared to placebo. There is no clinical evidence that lorecivivint regrows tendons or restores joint tissues to an adolescent state.

0:11:41overstatedmoderatePeter Diamandis and Tony Robbins on strategies that promote

In the three days following the spring transition into daylight saving time, heart attacks increase by an average of 24% across 70 countries.

"when we spring forward and we lose just one hour of sleep, in those 70 countries over the next three days, heart attacks increase like clockwork, on average, 24%." (said at 0:11:41)

The claim misrepresents a specific finding from a single US regional registry study as a global 70-country average. The cited 24% figure originates from a study of hospital admissions in Michigan (USA), which found a 24% increase in acute myocardial infarction admissions specifically on the single Monday immediately following the spring transition, with no significant increase on subsequent days and no increase in total weekly admissions. Comprehensive systematic reviews and meta-analyses pooling data across multiple countries report a far more modest increase of roughly 3% to 5% in relative risk following the spring transition (pooled RR ~1.04 to 1.05), while larger registry evaluations have found no statistically significant difference in weekly heart attack incidence.

0:11:51overstatedmoderatePeter Diamandis and Tony Robbins on strategies that promote

When falling back for daylight saving time and gaining one hour of sleep, heart attacks decrease by 21% across countries that observe it.

"When we fall back and get just one more hour of sleep, in all those countries, heart attacks dropped 21%." (said at 0:11:51)

The speaker claims that during the autumn 'fall back' clock change, heart attacks drop by 21% "in all those countries" that observe daylight saving time (DST). Large systematic reviews and meta-analyses examining global data show either no significant change or at most a non-significant, very tiny difference (~0% to 2%) in overall acute myocardial infarction (AMI) incidence during the autumn transition (PMID: 38888468, 30909587). The specific figure of a 21% reduction originates from a single study analyzing hospital data in Michigan (Sandhu et al., 2014; PMID: 25332784). However, this 21% reduction was observed only on a single day (the Tuesday following the fall transition), not as a weekly total or an overall effect, and certainly not across all countries observing DST. The total weekly rate of heart attack admissions in that study did not differ significantly following the fall transition.

0:12:02needs contextmoderatePeter Diamandis and Tony Robbins on strategies that promote

Men who sleep 4 to 5 hours a night typically have testosterone levels equivalent to someone 10 years older.

"He also showed me that a man who sleeps four to five hours a night usually has testosterone levels of a person 10 years older than they are." (said at 0:12:02)

Controlled laboratory research demonstrates that restricting sleep to 5 hours per night for one week reduces daytime testosterone levels in young healthy men by approximately 10% to 15%. Because normal aging is associated with an average testosterone decline of roughly 1% to 2% per year, this acute reduction represents an endocrine profile comparable to 10 to 15 years of aging. However, this comparison stems from short-term laboratory sleep-restriction protocols in small cohorts of young men rather than long-term epidemiological observations of habitual short sleepers.

0:20:28overstatedmoderatePeter Diamandis and Tony Robbins on strategies that promote

Sugar acts as a neuroinflammatory agent, causes cardiac disease, and accelerates cancer growth.

"gotten rid of sugar, right? It's like sugar equals poison, it's a neuroinflammatory, it causes cardiac disease, it feeds cancer, there are so many reasons." (said at 0:20:28)

The claim bundles several health effects of dietary sugar into broad, definitive assertions ('sugar equals poison', 'neuroinflammatory', 'causes cardiac disease', 'feeds cancer'). Large-scale systematic and umbrella reviews confirm that high dietary intake of added sugar and sugar-sweetened beverages is associated with increased risks of cardiovascular disease (such as coronary heart disease), adiposity, metabolic dysfunction, and certain cancers. Furthermore, preclinical and mechanistic reviews note that chronic high sugar intake can promote neuroinflammation and blood-brain barrier dysfunction via advanced glycation end products, oxidative stress, and insulin resistance. However, describing sugar categorically as a 'poison' that directly 'feeds cancer' overstates the evidence: glucose is an essential cellular metabolic substrate, and the epidemiological link between high sugar intake and cancer is largely indirect—mediated through excess caloric intake, obesity, hyperinsulinemia, and chronic inflammation rather than sugar directly accelerating cancer growth in isolation.

0:21:53unverifiedvery lowPeter Diamandis and Tony Robbins on strategies that promote

Among people in Peter Diamandis's demographic undergoing full-body preventative MRI screening, 2% have an undetected cancer, 2.5% have an undetected aneurysm, and 14.4% have an actionable finding.

"And it turns out historically for people in my age group, 2% have a cancer they don't know about, 2.5% have an aneurysm they don't know about, and 14.4% have something that's found that you need to take action on." (said at 0:21:53)

No published record matching the claim that 2% have an undetected cancer, 2.5% have an undetected aneurysm, and 14.4% have an actionable finding in this screening demographic was located; this does not prove the claim false.

0:22:26supportedhighPeter Diamandis and Tony Robbins on strategies that promote

The GRAIL Galleri liquid biopsy test can identify circulating cell-free DNA signals for 50 different types of cancer from a routine blood draw.

"Besides the full-body MRI, which is looking for cancers, we do a GRAIL, you know, liquid biopsy, which can find 50 different cancers in your bloodstream. It turns out as cancer cells are growing and dividing very rapidly, some of the cells rupture and you get free-floating DNA in the bloodstream. Well, GRAIL, which is now part of Illumina, started by Jeff Huber—we can we can tell his story—um, they were able to determine and find from a blood draw any number of 50 different cancer DNA sequences and and tell you you've got cancer someplace in your body." (said at 0:22:26)

The GRAIL Galleri multi-cancer early detection (MCED) test analyzes targeted methylation patterns of circulating cell-free DNA (cfDNA) in peripheral blood. In the clinical validation substudy of the Circulating Cell-free Genome Atlas (CCGA) study (NCT02889978; n = 4,077), the test demonstrated high specificity (99.5%) and detected cancer signals across more than 50 different cancer types, while accurately predicting the tissue/organ of origin in 88.7% of true positive cases.

0:23:29contradictedhighPeter Diamandis and Tony Robbins on strategies that promote

Coronary artery calcification (a high calcium score) represents stabilized plaque unlikely to rupture, whereas soft plaque is the primary driver of acute arterial blockage and heart attacks.

"Well, that's okay because a high calcium score means that the plaque in your coronary arteries have been calcified and they're unlikely to rupture. What really is a concern is soft plaque. And uh you've seen people with a zero calcium score having a heart attack where the plaque inside of the coronary arteries uh can rupture and then go and block the coronary artery, starve it from oxygen, your heart from oxygen, give you a heart attack." (said at 0:23:29)

The speaker claims that having a high coronary artery calcium (CAC) score is benign ("that's okay") because calcified plaques are stabilized and unlikely to rupture, and emphasizes soft plaque in individuals with a score of zero. This directly contradicts extensive prospective cardiovascular evidence. While dense focal calcification within a single plaque can alter local mechanical stress, a high CAC score reflects a large overall burden of coronary atherosclerosis (including extensive soft and mixed plaque) and is one of the strongest independent predictors of acute myocardial infarction and cardiac death. In landmark prospective cohort data from the Multi-Ethnic Study of Atherosclerosis (MESA), participants with CAC scores above 300 had a nearly tenfold higher risk of coronary events compared to those with a score of zero (hazard ratio 9.67). Conversely, a CAC score of zero is associated with an exceptionally low short- and intermediate-term event rate, rather than being the primary scenario for heart attacks.

0:25:46supportedmoderatePeter Diamandis and Tony Robbins on strategies that promote

Cleerly's AI-enabled coronary computed tomography angiography (CCTA) analysis can predict heart attacks up to five years in advance by quantifying soft coronary plaque.

"So he explained to me how it opens up the arteries and how you get this score, and they can predict a heart attack five years in advance and show you what to do." (said at 0:25:46)

AI-guided quantitative coronary computed tomography angiography (AI-QCT, including platforms like Cleerly) quantifies coronary plaque burden and composition, specifically noncalcified (soft) plaque and luminal stenosis. Multicenter prospective observational data, such as the CONFIRM2 registry (median 4.3 years follow-up), demonstrate that AI-derived noncalcified plaque volume and stenosis severity independently predict major adverse cardiovascular events and myocardial infarction over an approximate 5-year horizon, significantly improving risk discrimination over traditional cardiovascular risk scores and guiding targeted medical therapy.

0:32:20needs contexthighPeter Diamandis and Tony Robbins on strategies that promote

Sirtuins require NAD for fuel, and NAD requires NMN as a precursor.

"And the sirtuins need the NAD for fuel, but NAD needs NMN, as I know you know, as the precursor to make all that possible." (said at 0:32:20)

The biochemical relationship described is fundamentally accurate with respect to the mammalian NAD+ salvage pathway. Sirtuins are a family of deacetylases and deacylases that strictly require NAD+ as an obligate co-substrate (which is consumed during the reaction, colloquially described as 'fuel'). In turn, nicotinamide mononucleotide (NMN) is the direct intermediate produced by the rate-limiting enzyme NAMPT in the primary NAD+ salvage pathway before conversion to NAD+ by NMN adenylyltransferases. However, NAD+ can also be synthesized via alternative pathways using other dietary precursors, such as tryptophan (de novo pathway) and nicotinic acid (Preiss-Handler pathway).

0:32:20unverifiedvery lowPeter Diamandis and Tony Robbins on strategies that promote

A study testing products from six commercial NMN supplement companies found no NMN present in any of the tested products.

"with Dr. Sinclair, we studied six companies. We took their products to see how much NMN are you really getting, and there was none in any of the products." (said at 0:32:20)

No published record matching the specific claim that a study co-authored by Dr. Sinclair evaluated six commercial NMN supplement companies and found zero NMN present across all products was located; this does not prove the claim false.

0:32:48unverifiedvery lowPeter Diamandis and Tony Robbins on strategies that promote

Commercial NMN supplement products break down and become inert within 30 to 45 days.

"he said, "It breaks down in 30 to 45 days. So by the time somebody gets this product, it's usually inert."" (said at 0:32:48)

No published record matching the claim that commercial nicotinamide mononucleotide (NMN) supplement products break down and become inert within 30 to 45 days was located; this does not prove the claim false.

0:33:13overstatedvery lowPeter Diamandis and Tony Robbins on strategies that promote

A 20- to 24-month-old mouse runs a maximum of 0.25 km compared to 1 km for a young mouse, but 14 days of NMN treatment allows the older mouse to run 2 to 3 km.

"if you take an old mouse, meaning like a 70-year-old equivalent as a human, is about a 20- to 24-month mouse, as I'm sure you know, and you put them on, you know, a running platform, they can go maximum of a quarter of a kilometer, but a young, powerful mouse can do four times as much, a full kilometer. Well, 14 days on NMN, and now the NAD gets in, the absorption is about 30%, and that same animal that's equivalent of a 70-year-old animal will run two to three kilometers" (said at 0:33:13)

The speaker is referring to a preclinical mouse study from their laboratory (Das et al., 2018, PMID 29570999). In that study, 20-month-old mice ran approximately 240 meters (0.24 km) to exhaustion on a treadmill, compared to young mice running about 1,000 meters (1 km). Treatment with nicotinamide mononucleotide (NMN) significantly improved treadmill running endurance in the older mice (increasing distance and time by approximately 56% to 80%, reaching ~400–450 meters), but it did not enable them to run 2 to 3 kilometers. The claim substantially exaggerates the measured effect size, and the finding is restricted to animal models.

0:34:48supportedlowPeter Diamandis and Tony Robbins on strategies that promote

SARS-CoV-2 enters the mitochondria and depletes cellular energy, driving long-term fatigue.

"because I'm sure you know with COVID, it goes into your mitochondria and basically steals some of the energy, that's part of the problem with fatigue" (said at 0:34:48)

Research demonstrates that SARS-CoV-2 viral components (such as the envelope E protein) localize to host cell mitochondria, disrupting mitochondrial membrane potential, electron transport chain activity, and metabolic homeostasis. Clinical studies in patients with post-acute COVID-19 and Long COVID show impaired mitochondrial oxidative phosphorylation, decreased ATP generation, and mitochondrial dysfunction, which are key contributing factors to post-COVID fatigue.

Fact-checked episodes

Publications

No PubMed publication profile has been built for this speaker yet.